Fuji Pharma Co., Ltd. (JP:4554)
:4554
Top Page
Fuji Pharma Co., Ltd.
(4554)
Select Model
Select Model
Rating:68Neutral
Price Target:
¥2,681.00
▲(42.00% Upside)
Action:DowngradedDate:02/07/26
The score is driven primarily by solid financial progress (consistent revenue growth) but tempered by margin volatility, rising leverage, and only moderate cash conversion. Technicals are supportive due to a strong uptrend, though overbought RSI elevates near-term risk, while valuation is fair-to-moderate with a modest dividend yield.
Positive Factors
Consistent revenue growth
Sustained top-line expansion indicates steady demand for Fuji Pharma’s products and supports scalable R&D and commercial investment. Over 2–6 months this underpins recurring prescription revenue, strengthens negotiating position with distributors, and reduces reliance on one-off sales.
Negative Factors
Rising leverage
Increasing debt levels constrain financial flexibility and raise interest burden risk, especially if margins wobble. Over a 2–6 month horizon higher leverage can limit ability to invest in pipeline, increase refinancing vulnerability, and amplify earnings downside in downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth
Sustained top-line expansion indicates steady demand for Fuji Pharma’s products and supports scalable R&D and commercial investment. Over 2–6 months this underpins recurring prescription revenue, strengthens negotiating position with distributors, and reduces reliance on one-off sales.
Read all positive factors
Fuji Pharma Co., Ltd. (4554) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥63.11B
Dividend Yield2.39%
Average Volume (3M)86.41K
Price to Earnings (P/E)35.6
Beta (1Y)0.87
Revenue Growth12.01%
EPS Growth-51.38%
CountryJP
Employees1,658
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)13.28
Shares Outstanding26,121,100
10 Day Avg. Volume111,080
30 Day Avg. Volume86,410
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)0.80
Price to Sales (P/S)0.73
P/FCF Ratio9.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)152.3
Revenue Forecast (FY)¥53.93B
Fuji Pharma Co., Ltd. Business Overview & Revenue Model
Company Description
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products...
How the Company Makes Money
Fuji Pharma generates revenue mainly from the sale of prescription pharmaceuticals in Japan. Its core revenue stream comes from marketing and distributing its own branded and/or licensed products (including products focused on women’s health) to h...
Fuji Pharma Co., Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
65
Positive
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 51.68B | 46.14B | 40.89B | 35.43B | 33.99B |
| Gross Profit | 19.29B | 16.51B | 15.37B | 13.62B | 14.13B |
| EBITDA | 8.96B | 7.56B | 6.88B | 6.52B | 5.46B |
| Net Income | 3.00B | 6.15B | 3.44B | 2.70B | 2.43B |
Balance Sheet | |||||
| Total Assets | 93.63B | 90.58B | 86.40B | 75.97B | 64.26B |
| Cash, Cash Equivalents and Short-Term Investments | 7.25B | 4.58B | 2.32B | 3.55B | 10.20B |
| Total Debt | 30.94B | 29.25B | 28.95B | 24.57B | 18.66B |
| Total Liabilities | 46.72B | 45.01B | 45.22B | 40.17B | 31.58B |
| Stockholders Equity | 46.91B | 45.56B | 41.17B | 35.80B | 32.68B |
Cash Flow | |||||
| Free Cash Flow | 3.82B | 1.37B | -1.41B | -5.75B | 2.20B |
| Operating Cash Flow | 5.80B | 4.15B | 1.92B | -658.00M | 5.99B |
| Investing Cash Flow | -4.22B | -1.66B | -5.24B | -11.27B | -2.35B |
| Financing Cash Flow | 954.00M | -435.00M | 1.92B | 5.09B | -5.43B |
Fuji Pharma Co., Ltd. Technical Analysis
Positive
1888.00
Price Trends
2210.06
Positive
2005.00
Positive
1727.03
Positive
Market Momentum
60.98
Negative
62.03
Neutral
65.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4554, the sentiment is Positive. The current price of 1888 is below the 20-day moving average (MA) of 2297.75, below the 50-day MA of 2210.06, and above the 200-day MA of 1727.03, indicating a bullish trend. The MACD of 60.98 indicates Negative momentum. The RSI at 62.03 is Neutral, neither overbought nor oversold. The STOCH value of 65.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4554.
Fuji Pharma Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥69.27B | 8.62 | ― | 2.52% | 5.44% | -20.33% | |
73 Outperform | ¥119.61B | 12.60 | 4.81% | 2.34% | 4.35% | 48.30% | |
69 Neutral | ¥89.22B | 8.41 | ― | 3.36% | 11.65% | 93.46% | |
68 Neutral | ¥63.11B | 35.63 | 5.01% | 2.39% | 12.01% | -51.38% | |
63 Neutral | ¥43.15B | 18.30 | ― | 2.75% | 7.56% | -48.91% | |
60 Neutral | ¥20.70B | 5.79 | ― | 3.71% | 7.50% | -281.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4554
Fuji Pharma Co., Ltd.
2,460.00
1,308.70
113.67%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,515.00
678.28
23.91%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,360.00
399.93
20.40%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,695.00
377.53
28.66%
JP:4577
Daito Pharmaceutical Co., Ltd.
1,434.00
439.62
44.21%
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,603.00
558.31
27.31%
Fuji Pharma Co., Ltd. Corporate Events
Fuji Pharma Lifts Interim Dividend Forecast on Solid Core Product Sales
Mar 19, 2026
Fuji Pharma Co., Ltd. has revised its interim dividend forecast for the fiscal year ending September 2026 after confirming that sales of its main products are generally progressing smoothly and that its financial position remains sound. The compan...
Fuji Pharma Raises ¥3.3 Billion as 2nd Series Stock Acquisition Rights Fully Exercised
Mar 11, 2026
Fuji Pharma Co., Ltd. announced that the entire 2nd Series of Stock Acquisition Rights, issued via third-party allotment to Nomura Securities Co., Ltd. in August 2024, has been fully exercised as of March 11, 2026. The exercise of all 16,500 units...
Fuji Pharma Lifts Sales Outlook but Slashes Profit Forecast on Alvotech Valuation Loss
Feb 5, 2026
Fuji Pharma revised its earnings forecasts for the second quarter and full year ending September 2026, projecting higher net sales, operating profit and ordinary profit on the back of stronger-than-expected sales of its main products, while keepin...
Fuji Pharma Books ¥2.46 Billion Securities Valuation Loss on Alvotech Stake
Feb 5, 2026
Fuji Pharma has recognized an impairment loss on its portfolio of available-for-sale securities for the first quarter of the fiscal year ending September 2026, booking a valuation loss of ¥2,457 million after a significant decline in the shar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.